Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Sigilon Therapeutics, Inc. (NASDAQ: SGTX) to Eli Lilly and Company is fair to Sigilon shareholders. Under the terms of the agreement, Eli Lilly would acquire all outstanding shares of Sigilon for $14.92 per share in cash payable at closing, plus one non-tradeable contingent value right per share that entitles the holder to receive up to an additional $111.64 per share in cash.

Halper Sadeh encourages Sigilon shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

The investigation concerns whether Sigilon and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Sigilon shareholders; (2) determine whether Eli Lilly is underpaying for Sigilon; and (3) disclose all material information necessary for Sigilon shareholders to adequately assess and value the merger consideration. On behalf of Sigilon shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Halper Sadeh encourages Sigilon shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230629848145/en/